BioSpaceOriginal article
GSK to launch Phase 3 trial for mRNA-based flu vaccine amid resurgence for the modality
Phase 3GSK mRNA flu vaccineModerna mRNA flu vaccinePositive
AI Analysis
Summary
GSK is launching a Phase 3 trial in September for its mRNA-based flu vaccine, which demonstrated higher immune responses in both younger and older adults in Phase 2 data. The advancement follows FDA approval of Moderna's mRNA flu vaccine.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Phase 3 trial planned for launch in September; Phase 2 data showed higher immune responses in younger and older adults
Importance:7/10
Sentiment:
0.60
mRNA vaccineinfluenzaPhase 3GSKclinical trialModerna
Related Companies
Read the original article
Published by BioSpace on September 1, 2026 2:09 PM